REG - Immupharma PLC - Interim Results or the 6mths Ended 30 June 2022
30/09/2022 07:01
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220930:nRSd2513Ba&default-theme=true
RNS Number : 2513B Immupharma PLC 30 September 2022
RNS: RELEASE | 30 SEPTEMBER 2022
ImmuPharma PLC
("ImmuPharma" or the "Company")
INTERIM RESULTS
for the six months ended 30 June 2022
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug
discovery and development company, is pleased to announce its interim results
for the six months ended 30 June 2022 (the "Period").
Key Highlights (including post Period review)
Financials
· Financial performance in line with expectations over the Period
o Loss for the Period of £1.7m (30 June 2021: £3.7m)
o Research and development expenses of £1.0m (30 June 2021: £1.1m)
o Administrative expenses of £0.6m (30 June 2021: £0.9m)
o Share based expense of £0.1m (30 June 2021: £0.3m)
o Cash balance of £0.2m as at 30 June 2022 (31 December 2021: £1.6m)
o Derivative financial asset of £0.6m as at 30 June 2022 (31 December 2021:
£0.9m)
o Incanthera financial asset of £0.6m (£1.2m at 31 December 2021) and
warrants financial asset of £Nil (£0.2m at 31 December 2021)
o Basic and diluted loss per share of 0.58p (30 June 2021: 1.46p)
o Reorganisation of share capital structure in June 2022
o Successful fundraising in August 2022 raising £2.04m (gross), including
Lanstead subscription, placement and broker option
o Total proceeds of £0.3m from exercise of share options by L1 Capital in
August 2022 and in September 2022
'Autoimmunity': Lupuzor™ ("P140")
· P140 Pharmokinetic ("PK") study successfully completed with key
endpoints met. P140 was safe and well tolerated across all doses and in all
subjects
· FDA Type C written response received on 14 September 2022: The FDA
response was detailed and included significant guidance on next steps for the
clinical programme. This included advice on the dosing regime and on study
protocol that can be amended to improve the regulatory outcome
· The Company is currently reviewing the written response with Avion and
will make a further notification in due course
· An adaptive Phase 2/3 clinical study protocol of P140 in CIDP is being
finalised for IND submission. Commercial partnering discussions ongoing
'Anti-Infection'
· BioAMB - further pre-clinical studies are in preparation
· BioCin - further pre-clinical studies are in preparation
New website launched: www.immupharma.co.uk
Commenting on the statement and outlook, Tim McCarthy, CEO and Chairman, said:
"The last six months have been pivotal for the Company, positively concluding
the PK study of Lupuzor™ ("P140"). Post the recent written response from the
FDA, in respect to the Lupuzor™ Phase 3 protocol, we continue to have
positive discussions with our partner, Avion, on the way forward.
The new fundraising, supported by existing and new shareholders, allows us to
further invest in the other parts of our product portfolio, whilst being
focused on preserving cash where required.
Moving forward, we remain focused on creating a robust and successful Company
that, with a diversity of assets, will build future value for our
shareholders.
The Board would like to take this opportunity to thank its shareholders for
their continued patience and support, as well as its staff, corporate and
scientific advisers and our partners including, CNRS and Avion".
Market Abuse Regulation (MAR) Disclosure
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK
VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF UK LAW BY
VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. ON
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
For further information please contact:
ImmuPharma PLC (www.immupharma.co.uk) + 44 (0) 2072 062650
Tim McCarthy, Chief Executive Officer and Chairman
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD) +44 (0) 203 368 8974 (tel:0113%20370%208974)
Neil Baldwin
Stanford Capital Partners (Joint Broker) +44 (0) 203 815 8880
Patrick Claridge, John Howes
SI Capital (Joint Broker) +44 (0) 1483 413500
Nick Emerson
A copy of the interim report is available on the Company's website
www.immupharma.co.uk
ImmuPharma plc
Chairman's Statement
INTERIM HIGHLIGHTS
The first half of 2022 up to the current date has seen a number of key
developments for ImmuPharma, including completion of pharmacokinetic ("PK")
study of Lupuzor™. In addition, in June 2022, our share capital structure
has been reorganised and in August 2022, we concluded a successful
fundraising.
Lupuzor™
The Board is confident that there are a number of routes to market for
Lupuzor™, including corporate collaborations. Such a collaboration was
successfully completed at the end of November 2019, resulting in a signed
exclusive Trademark, License and Development Agreement with Avion
Pharmaceuticals ("Avion") in the US. Positive discussions with a number of
potential commercial partners for Lupuzor™ in key territories outside of the
US are continuing.
Lupuzor™ and Avion Pharmaceuticals | Background
On 28 November 2019, ImmuPharma and Avion signed an exclusive Trademark,
License and Development Agreement for Lupuzor™, with Avion agreeing to fund
a new international Phase 3 trial and commercialising Lupuzor™ in the US.
There have been many meetings following this agreement with both Avion and the
FDA, which have been highlighted in numerous announcements.
As part of these discussions, the FDA requested that Avion and ImmuPharma
develop and validate a bioanalytical assay in order to confirm the unique
pharmacokinetic ("PK") profile of Lupuzor™/ P140, principally to demonstrate
that P140 shows a positive result within plasma at the subcutaneous level.
The P140 PK study was successfully completed, as announced on 13 April 2022,
with all key endpoints requested by the FDA being met. The key highlights from
the study were summarised as below.
Subcutaneous injection of P140 (in both 200 microgram ("mcg") and 800 mcg
doses (note: 1mcg = 1 millionth of a gram) showed a clear time and
dose-related PK profile, which is detectable in the blood of human volunteers
and applicable for all potential clinical dosing regiments of P140.
The final group of subjects completed dosing on 30 March 2022. This was a
group of subjects that received an intravenous injection of a 800 mcg dose of
P140, which showed successful measurement of the absolute bioavailability of
the drug (as a control). In line with all human dosing to date, P140 was safe
and well tolerated across all doses and in all subjects.
Avion, our US partner, has been integral to the development, initiation and
successful conclusion of this PK study.
On 27 June 2022 Avion submitted, via a Type C Meeting, the positive results
from the Lupuzor™/P140 PK study to the FDA.
The FDA response, reported on 14 September 2022 was detailed and included
significant guidance on next steps for the clinical programme. This included
advice on the dosing regime and on study protocol that can be amended to
improve the regulatory outcome.
The Company is currently reviewing the written response with Avion and will
make a further notification in due course.
Pipeline Overview
ImmuPharma's pipeline is focused on two core therapeutic areas:
· Autoimmunity & Inflammation
· Anti-Infectives
Autoimmunity & Inflammation
The increasing knowledge of P140's mode of action and its relevance to many
autoimmune and inflammatory conditions provides a depth of disease states for
ImmuPharma and its partners to explore in the near future. The therapeutic
potential of P140 goes beyond just lupus, with Chronic Inflammatory
Demyelinating Polyneuropathy ("CIDP") being the next step. This expanding
insight is fundamentally driven by the excellent research partnership between
the Company and Prof. Sylviane Muller, inventor of P140 and Emeritus Research
Director CNRS, France. Key highlights within the progression of the P140
platform are summarized below:
o Lupuzor™ (P140) - successfully completed PK study
o P140 - CIDP a neurological disorder targeting the body's nerves. An
adaptive Phase 2/3 clinical study protocol is being finalised for IND
submission
o P140 - Other indications. Further clinical applications based on further
preclinical investigation include asthma, Sjögrens syndrome, irritable bowel
disease, periodontitis and gout
o P140 - Second generation. 'ImmuPharma Biotech' has commenced work to
develop a pharmacologically improved version of P140, a second-generation
product that aims to further strengthen the IP position and provide therapies
with different improved administration modalities, yet still maintaining P140
as the active moiety
Anti-Infectives
The innovative peptide technology at ImmuPharma Biotech has been a huge
success and very recently has given rise to a number of novel development
programs, out of which we have identified two core programs, in pre-clinical
development; BioAMB and BioCin, which we believe have the best commercial
opportunity and speed to market.
o BioAMB, a novel peptide-based drug that offers a potential improvement on
the limiting side effects and poor administration regime of current
Amphotericin-B ("AMB") formulations. AMB is one of a last line of agents
against serious and life-threatening fungal infections caused by the
aspergillus family of fungi
o BioCin, a novel peptide-based drug based on an existing potent
antibacterial used in high medical need cases and in many cases the last line
of defense. BioCin has the potential to offer improved safety and/or
administration benefits
Capital restructure
At the Annual General Meeting on 28 June 2022, the shareholders approved the
subdivision of the Company's ordinary share capital, whereby each existing
Ordinary Share with a nominal value of 10p was subdivided into 1 new Ordinary
Share of 1p and 1 Deferred Share of 9p. The Deferred Shares have no
significant rights attached to them and carry no right to vote or to
participate in distribution of surplus assets and are not admitted to trading
on the AIM market of the London Stock Exchange plc. The Deferred Shares
effectively carry no value.
Capital subscription
In August 2022, ImmuPharma completed a successful fundraising totalling
£2.04m (before expenses) through the issue of 40,818,182 new ordinary shares
of 1p each in ImmuPharma, at a price of 5p per ordinary share ("Issue Price").
The highlights of the August 2022 fundraising are outlined below:
o Subscription for 20,000,000 new ordinary shares by Lanstead Capital
Investors L.P. "Lanstead" to raise £1 million (at 5p per share)
o "Placing" of 1,818,182 new ordinary shares to raise £0.09 million at the
price of 5p.
o "Broker Option" raised an additional £0.95 million, for 19 million shares
at the price of 5p per share. Certain the Directors (Tim McCarthy, Dr Tim
Franklin, Lisa Baderoon) subscribed to £0.1m in total in the Broker Option
(£60,000, £20,000, £20,000 respectively).
o 200,000 new ordinary shares ("Fee Shares") at an issue price of 5p per
share to SPARK Advisory Partners Limited, the Company's nominated adviser, in
lieu of fees.
Lanstead subscription
The £1 million gross proceeds of the Lanstead subscription were followed by
the Sharing Agreement with Lanstead for 100% of these shares with a reference
price of 6.6667p per share ("Benchmark Price"). The Sharing Agreement is for a
24 month period and the Company will receive 24 equal monthly settlements, as
measured against Benchmark Price. The actual consideration is variable
depending upon ImmuPharma's share price, which needs to be on average (over
the 24 months of the sharing agreement) at or above the Benchmark price for
the Company to receive at least, or more than, the gross subscription of £1
million.
For example, if on a monthly settlement date the calculated "Measured Price"
(average of twenty day ImmuPharma share VWAP) exceeds the Benchmark Price by
10 per cent, the settlement on that monthly settlement date will be 110 per
cent of the amount due from Lanstead on that date. If on the monthly
settlement date the calculated "Measured Price" is below the Benchmark Price
by 10 per cent, the settlement on the monthly settlement date will be 90 per
cent of the amount due on that date.
The Company also agreed to issue Lanstead 1,400,000 ordinary shares in
connection with entering into the Sharing Agreement ("Value Payment Shares").
Impact on L1/Lind arrangement
The 25,640,254 options in the Company, held equally by L1 Capital Global
Opportunities Master Fund "L1" and Lind Global Macro Fund, LP "Lind" issued on
11 June 2020, exercisable at any time up to 10 June 2023, at 11p have been
amended, as a result of the August 2022 fundraising of issuing shares below
11p. The effect of the current fundraising is to amend the exercise price of
this options from 11p to 5p and to increase the number of options held by L1
and Lind from 25,640,254 to 56,408,558.
Warrants
In August 2022, Lanstead was issued 30,000,000 warrants (for 10 years term),
with an exercise price of 5.5p per share in return for foregoing the
entitlement to increase the benchmark price by 50% (from 14.6667p to 22p) in
relation to the 2021 sharing agreement (due to the amendment made to L1 and
Lind option arrangements).
In August 2022, Stanford Capital Partners ("SCP"), the Company's broker, was
issued 2,000,000 warrants with an exercise price of 5p per share for the
period of 10 years, in lieu of fees.
In August 2022, SCP and SI Capital were issued 500,000 warrants each, for a
period of 10 years, in lieu of fees, as part of the "Broker Option".
Exercise of options
On 24 August 2022, L1 has exercised options over 1,000,000 new ordinary shares
of 1p each at an exercise price of 5p per share, for a consideration of
£50,000.
On 30 August 2022, L1 has exercised options over 2,000,000 new ordinary shares
of 1p each at an exercise price of 5p per share, for a consideration of
£100,000.
On 7 September 2022, L1 has exercised options over 3,000,000 new ordinary
shares of 1p each at an exercise price of 5p per share, for a consideration of
£150,000.
Interest in Incanthera Plc
ImmuPharma has a 13.37% interest in Incanthera plc, which trades on Aquis
Stock Exchange ("AQSE") under the ticker (TIDM:INC).
ImmuPharma also has 7,272,740 warrants options in Incanthera at an exercise
price of 9.5p, being the price at which new shares have been issued in the
Placing accompanying Incanthera's listing.
Please refer to Incanthera's website for further updates on the company
(www.incanthera.com (http://www.incanthera.com) ).
Financial Review
ImmuPharma's cash balance at 30 June 2022 was £0.2 million (£1.6 million at
31 December 2021, £4.2 million at 30 June 2021) with the decrease in the
Period caused by the research and development expenditure related to PK study.
Financial asset related to investment in Incanthera plc amounted to £0.6
million (£1.2 million at 31 December 2021, £1.2 million at 30 June 2021) and
warrants (recognized under financial asset) decreased to £Nil (£0.2 million
at 31 December 2021 and £0.2 million at 30 June 2021). The decrease was due
to the fair value loss on the investment in shares in the Incanthera plc,
following the decrease in its share price to 6p at 30 June 2022 compared to
12.2p at 31 December 2021.
As a result of the Lanstead Sharing Agreements, the Company had a derivative
financial asset of £0.6 million at 30 June 2022 (£0.9 million at 31 December
2021, £0.2 million at 30 June 2021). The decrease was a result of the fair
value calculation performed at 30 June 2022, reflecting the decrease in
ImmuPharma's share price. Current tax asset amounted to £0.6 million at 30
June 2022 (£0.8 million at 31 December 2021, £0.2 million at 30 June 2021)
and it's related to research and development tax credit due. The convertible
loans liability has been repaid in full in 2021, therefore it has a £Nil
balance (£Nil at 31 December 2021, £0.7 million at 30 June 2021). Trade and
other payables liability decreased to £0.9 million at 30 June 2022 (£1.6
million at 31 December 2021, £1.1 million at 30 June 2021) and was largely
due to payments made for PK study related expenditures. Basic and diluted loss
per share were 0.58p and 0.58p respectively (30 June 2021: 1.46p and 1.46p).
In line with the Company's current policy, no interim dividend is proposed.
Operating loss for the Period was £1.7 million (£3.1 million for the six
months ended 30 June 2021). Research and development expenditure in the
Period was £1 million (£1.1 million for the six months ended 30 June 2021).
Administrative expenses decreased to £0.6 million during the Period (£0.9
million for the six months ended 30 June 2021), largely due to savings made on
corporate reorganization. The share based expense amounted to £0.1 million
(£0.3 million for the six months ended 30 June 2021). Finance costs for the
Period were £0.2 million (£0.9 million for the six months ended 30 June
2021). These arose largely due to the calculation of fair value of the
derivative financial asset - "Lanstead Sharing Agreements", which resulted in
a finance loss of £0.2 million (£0.8 million of finance loss for the six
months ended 30 June 2021). The finance loss was significant for the six
months ended 30 June 2021, due to the impact of the adjustment to the Lanstead
Sharing Agreements' benchmark price from 13.33p to 20p. Finance income for the
Period was £0.02 million (£0.1 million for the six months ended 30 June
2021). It primarily arose due to foreign exchange gain.
Given the stage of ImmuPharma's development, the fact that losses have
continued to be made is to be expected since there is minimal revenue and
business activity is concerned with significant investment in the form of
clinical development expenditure, in addition to maintaining the
infrastructure of the Company.
Current activities and outlook
The last six months have been pivotal for the Company, positively concluding
the PK study of Lupuzor™ ("P140"). Post the recent written response from the
FDA, in respect to the Lupuzor™ Phase 3 protocol, we continue to have
positive discussions with our partner, Avion, on the way forward.
The new fundraising, supported by existing and new shareholders, allows us to
further invest in the other parts of our product portfolio, whilst being
focused on preserving cash where required.
Moving forward, we remain focused on creating a robust and successful Company
that, with a diversity of assets, will build future value for our
shareholders.
The Board would like to take this opportunity to thank its shareholders for
their continued patience and support, as well as its staff, corporate and
scientific advisers and our partners including, CNRS and Avion.
Tim McCarthy
Chairman & Chief Executive Officer
ImmuPharma plc
CONSOLIDATED INCOME STATEMENT
FOR THE PERIOD ENDED 30 JUNE 2022
Unaudited Audited Year ended 31 December 2021 Unaudited 6 months ended
6 months ended 30 June 2021
30 June 2022 restated*
Note
£ £ £
Continuing operations
Revenue - 118,350 23,531
Research and development expenses (1,042,917) (3,650,400) (1,054,875)
Administrative expenses (555,600) (1,011,398) (913,516)
Exceptional items 6 - (1,427,084) (846,792)
Share based expense (70,994) (616,423) (288,826)
(1,669,511) (6,586,955)
Operating loss (3,080,478)
Finance costs 4 (176,665) (2,354,872) (904,549)
Finance income 16,364 1,107 95,225
Loss before taxation (1,829,812) (8,940,720) (3,889,802)
Tax 166,024 766,815 229,919
Loss for the period (1,663,788) (8,173,905) (3,659,883)
Attributable to:
Equity holders of the parent company (1,663,788) (8,173,905) (3,659,883)
Loss per ordinary share
Basic and diluted 2 (0.58)p (3.25)p (1.46)p
* The presentation of the income statement for the comparative period ended 30
June 2021 has been restated to show exceptional items as a separate line,
consistent with the presentation for the full year income statement for the
year ended 31 December 2021.
ImmuPharma plc
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE PERIOD ENDED 30 JUNE 2022
Unaudited Audited Year Unaudited 6 months ended
6 months ended ended 31 December 2021 30 June
30 June 2021
2022
£ £ £
Loss for the financial period (1,663,788) (8,173,905) (3,659,883)
Other comprehensive income
Items that will not be reclassified subsequently to profit or loss:
Fair value loss on investment (614,068) (584,355) (555,633)
Fair value loss on warrants (206,411) (418,068) (395,640)
Total items that will not be reclassified subsequently to profit or loss (820,479) (1,002,423) (951,273)
Items that may be reclassified subsequently to profit or loss:
Exchange differences on translation of foreign operations 16,350 (36,177) (20,357)
Total items that may be reclassified subsequently to profit or loss 16,350 (36,177) (20,357)
Other comprehensive loss for the period (971,630)
(804,129) (1,038,600)
Total comprehensive loss for the period (2,467,917) (9,212,505) (4,631,513)
ImmuPharma plc
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 30 JUNE 2022
Note Unaudited Audited Year Unaudited 6 months ended
6 months ended ended 31 December 2021 30 June
30 June 2021
2022
£ £ £
Non-current assets
Intangible assets 471,534 477,553 495,736
Property, plant and equipment 330,835 352,996 369,700
Financial asset 595,355 1,415,835 1,466,985
Derivative financial asset 4 196,488 405,489 -
Total non-current assets 1,594,212 2,651,873 2,332,421
Current assets
Trade and other receivables 114,450 427,199 129,850
Cash and cash equivalents 170,922 1,649,374 4,248,412
Current tax asset 595,205 761,188 211,180
Derivative financial asset 4 400,306 508,167 160,436
Total current assets 1,280,883 3,345,928 4,749,878
Current liabilities
Financial liabilities - borrowings (230) (700) (914)
Trade and other payables (858,291) (1,583,604) (1,113,465)
Convertible loans - - (655,811)
Total current liabilities (858,521) (1,584,304) (1,770,190)
Net current assets 422,362 1,761,624 2,979,688
Net assets 2,016,574 4,413,497 5,312,109
EQUITY
Ordinary shares 5 2,849,849 28,498,494 25,022,130
Deferred shares 5 25,648,645 - -
Share premium 27,237,329 27,237,329 27,237,329
Merger reserve 106,148 106,148 106,148
Other reserves 5,240,503 5,153,159 3,524,005
Retained earnings (59,065,900) (56,581,633) (50,577,503)
Total equity 2,016,574 4,413,497 5,312,109
ImmuPharma plc
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE PERIOD ENDED 30 JUNE 2022
Ordinary shares Deferred shares Other reserves -Share based payment reserve Total
£ £ £ Equity
£
Other reserves - Convertible option reserve
£
Other Other Other reserves - Warrant reserve
reserves - reserves - £
Share premium Merger Acquisition Translation Retained
£ Reserve Reserve Reserve Earning
£ £ £ £s
At 1 January 2021 25,022,130 - 27,237,329 106,148 (3,541,203) (1,308,480) 8,073,596 31,623 - (45,966,347) 9,654,796
Loss for the financial period - - - - - - - - (3,659,883) (3,659,883)
Exchange differences - - - - - (20,357) - - - (20,537)
Share based payments - - - - - - 288,826 - - 288,826
Equity component of convertible loan notes - - - - - - - - - -
Fair value loss on investments - - - - - - - - (555,633) (555,633)
Fair value loss on warrants - - - - - - - - (395,640) (395,640)
At 30 June 2021 unaudited 25,022,130 - 27,237,329 106,148 (3,541,203) (1,328,837) 8,362,422 31,623 - (50,577,503) 5,312,109
At 1 January 2021 25,022,130 - 27,237,329 106,148 (3,541,203) (1,308,480) 8,073,596 31,623 - (45,966,347) 9,654,796
Loss for the financial year - - - - - - - - (8,173,905) (8,173,905)
Exchange differences - - - - (36,177) - - - (36,177)
Share based payments - - - - - - 616,423 - - 616,423
Settlement of convertible loans reserves (31,623) 31,623 -
New issue of equity capital 3,476,364 - 322,727 - - - - - (1,349,000) 2,450,091
Cost of new issue of equity capital - - (322,727) - - - - - (121,581) (444,308)
Fair value loss on investments - - - - - - - - (584,355) (584,355)
Fair value loss on warrants - - - - - - - - (418,068) (418,068)
Issue of warrants - 1,349,000 - 1,349,000
At 31 December 2021 & 1 January 2022 audited 28,498,494 - 27,237,329 106,148 (3,541,203) (1,344,657) 8,690,019 - 1,349,000 (56,581,633) 4,413,497
Loss for the financial period - - - - - - - - - (1,663,788) (1,663,788)
Exchange differences 16,350 16,350
- - - - - - - -
Share split (25,648,645) 25,648,645 -
Share based payments - - - - - - 70,994 - - - 70,994
Fair value loss on investments - - - - - - - - - (614,068) (614,068)
Fair value loss on warrants - - - - - - - - - (206,411) (206,411)
At 30 June 2022 unaudited 2,849,849 25,648,645 27,237,329 106,148 (3,541,203) (1,328,307) 8,761,013 - 1,349,000 (59,065,900) 2,016,574
ImmuPharma plc
CONSOLIDATED STATEMENT OF CASHFLOWS
FOR THE PERIOD ENDED 30 JUNE 2022
Note Unaudited Audited Year Unaudited 6 months ended
6 months ended ended 31 December 2021 30 June
30 June 2021
2022
£ £ £
Cash flows from operating activities
Cash used in operations 3 (1,966,598) (5,222,446) (2,068,937)
343,246 392,217 390,418
Tax received
Interest paid (922) (2,943) (1,444)
(1,624,274) (4,833,172)
Net cash used in operating activities (1,679,963)
Investing activities
Purchase of property, plant and equipment - (50,934)
(48,014)
Purchase of intangibles - - (4,756)
Interest received 63 651 215
Net cash (used in)/generated from investing activities 63 (50,283) (52,555)
Financing activities
Decrease in bank overdraft - (211) 5
New loans/(loan repayments) (470) (6,028) (5,751)
Settlements from Sharing Agreement 143,273 328,495 261,116
Gross proceeds from issue of new share capital - 3,550,000 -
Share capital issue costs - (132,350) -
Funds deferred per Sharing Agreement - (2,200,000) -
Interest paid on convertible loan notes - (121,120) -
Convertible loan notes repaid - (716,739) -
Net cash generated from financing activities 142,803 702,047 255,370
Net (decrease) in cash and cash equivalents (1,481,408) (4,181,408) (1,477,148)
Cash and cash equivalents at start of period 1,649,374 5,862,057 5,862,057
Effects of exchange rates on cash and 2,956 (31,275) (136,497)
cash equivalents
1,649,374
Cash and cash equivalents at end of period 170,922 4,248,412
ImmuPharma plc
NOTES TO THE CONSOLIDATED INTERIM ACCOUNTS FOR THE PERIOD ENDED 30 JUNE 2022
1 ACCOUNTING POLICIES
Basis of preparation
The interim financial information in this report has been prepared using
accounting policies consistent with IFRS as adopted by the United Kingdom.
IFRS is subject to amendment and interpretation by the International
Accounting Standards Board (IASB) and the IFRS Interpretations Committee and
there is an ongoing process of review and endorsement by the UK Endorsement
Board. The financial information has been prepared on the basis of IFRS
expected to be adopted by the United Kingdom and applicable as at 31 December
2022. The Group has chosen not to adopt IAS 34 "Interim Financial Statements"
in preparing the interim financial information.
The accounting policies applied are consistent with those that were applied to
the financial statements for the year ended 31 December 2021.
Non-Statutory accounts
The financial information set out in this interim report does not constitute
the Group's statutory accounts, within the meaning of Section 434 of the
Companies Act 2006. The statutory accounts for the year ended 31 December 2021
have been filed with Registrar of Companies. The auditors reported on those
accounts; their report was unqualified, did not contain a statement under
either Section 498 (2) or Section 498 (3) of the Companies Act 2006 but did
include emphasis of matter paragraph relating to the carrying value of Parent
Company's investment in subsidiaries and receivables due from group
undertakings, and a reference to which the auditor drew attention by way of
emphasis without qualifying their report in respect of going concern.
Copies of this statement will be available on the
Company's website - www.immupharma.co.uk.
2 LOSS PER SHARE
Unaudited Audited Year Unaudited 6 months ended
6 months ended ended 31 December 2021 30 June
30 June 2021
2022
£ £ £
Loss
Loss for the purposes of basic and diluted loss per share being net loss (1,663,788) (8,173,905) (3,659,883)
attributable to equity shareholders
Number of shares
Weighted average number of ordinary shares for the purposes of basic loss per 284,984,933 251,164,361 250,221,297
share
(0.58)p (3.25)p (1.46)p
Basic loss per share
Diluted loss per share (0.58)p (3.25)p (1.46)p
There is no difference between basic loss per share and diluted loss per share
as the share options and warrants are anti-dilutive. Deferred shares are
excluded from the loss per share calculation as they have no attributable
earnings.
3 CASH USED IN OPERATIONS
Unaudited Audited Year Unaudited 6 months ended
6 months ended ended 31 December 2021 30 June
30 June 2021
2022
£ £ £
Operating loss (1,669,511) (6,586,955) (3,080,478)
Depreciation & amortisation 37,212 114,119 86,639
Share based payments 70,994 616,423 288,826
Decrease/(increase) in trade & other receivables 312,749 (265,201) 29,964
Increase/(decrease) in trade & other payables (725,313) 896,798 511,100
Gain on foreign exchange 7,271 2,370 95,012
Cash used in operations (1,966,598) (5,222,446) (2,068,937)
4 Derivative Financial Asset
As part of the placement completed in June 2019, the Company issued 26,565,200
new ordinary shares to Lanstead Capital Investors L.P. ("Lanstead") at a price
of 10p per share for an aggregate subscription price of £2.66m before
expenses. In the placement completed in March 2020, the Company issued
13,000,000 new ordinary shares to Lanstead at a price of 10p per share to
raise £1.3m gross. In December 2021, the Company issued 20,000,000 new
ordinary shares to Lanstead at a price of 11p per share to raise £2.2m before
expenses. All Subscriptions proceeds were pledged under the Sharing Agreement,
under which Lanstead made and will continue to make, subject to the terms and
conditions of that Sharing Agreement, monthly settlements to the Company that
are subject to adjustment upwards or downwards depending on the Company's
share price performance.
In December 2021 the Company also issued 1,400,000 new ordinary shares to
Lanstead as value payments in connection with the Share Subscription and the
Sharing Agreement. Monthly settlements under the Sharing Agreement from June
2019 completed in September 2021. The settlements from remaining agreements
(March 2020 and December 2021) will continue until 2024, completing in July
2022 and March 2024 respectively.
At the end of the accounting period the amount receivable has been adjusted to
fair value based upon the share price of the Company at that date. Any change
in the fair value of the derivative financial asset is reflected in the income
statement. As at 30 June 2022, the Company completed a calculation of fair
value of the derivative financial asset that resulted in a finance loss of
£175,742 (£769,570 at 30 June 2021), which was recorded in the income
statement. The restatement to fair value will be calculated at the end of each
accounting period during the course of the Sharing Agreement and will vary
according to the Company's share price performance.
5 Issued share capital
Allotted, called up and fully paid Ordinary Shares 30 June 2022 31 December 2021 No. 30 June 2022 31 December 2021 £
No. £
At start of period 284,984,933 250,221,297 28,498,494 25,022,130
of £0.10 each
Split to deferred shares of £0.09 each - - (25,648,645) -
Shares issued in the period
- - - -
At end of period
of £0.01 each
284,984,933 250,221,297 2,849,849 25,022,130
Allotted, called up and fully paid Deferred Shares 30 June 2022 31 December 2021 No. 30 June 2022 31 December 2021 £
No. £
At start of period - - - -
Split from Ordinary Shares of £0.09 each 284,984,933 - 25,648,645 -
At end of period of £0.09 each
284,984,933 - 25,648,645 -
Capital restructure
At Annual General Meeting on 28 June 2022 the shareholders approved the
subdivision of the Company's ordinary share capital, whereby each existing
Ordinary Share with a nominal value of 10p was subdivided into 1 new Ordinary
Share of 1p and 1 Deferred Share of 9p. The Deferred Shares have no
significant rights attached to them and carry no right to vote or to
participate in distribution of surplus assets and are not admitted to trading
on the AIM market of the London Stock Exchange plc. The Deferred Shares
effectively carry no value.
6. Exceptional items
There were no exceptional items in the Period (£1.4 million at 31 December
2021, £0.8 million at 30 June 2021). Exceptional items related to termination
benefit packages paid out in 2021.
7. Subsequent events
In August 2022 ImmuPharma secured successful fundraising totalling to £2.04m
(before expenses) through the issue of 40,818,182 new ordinary shares of 1p
each in ImmuPharma at a price of 5p per ordinary share ("Issue Price").
The highlights of the August 2022 fundraising are outlined below:
o -Subscription for 20,000,000 new ordinary shares by Lanstead Capital
Investors L.P. "Lanstead" to raise £1 million (at 5p per share).
o -"Placing" of 1,818,182 new ordinary shares to raise £0.09 million at the
price of 5p.
o -"Broker Option" raised an additional £0.95 million, for 19 million
shares at the price of 5p per share. Certain of the Directors (Tim McCarthy,
Dr Tim Franklin, Lisa Baderoon) subscribed £0.1m in total in the Broker
Option (£60,000, £20,000, £20,000 respectively).
o -200,000 new ordinary shares ("Fee Shares") at an issue price of 5p per
share to SPARK Advisory Partners Limited, the Company's nominated adviser, in
lieu of fees.
Lanstead subscription
The £1 million gross proceeds of the Lanstead subscription was followed by
the Sharing Agreement with Lanstead for 100% of these shares with a reference
price of 6.6667p per share ("Benchmark Price"). The Sharing Agreement is for a
24 month period and the Company will receive 24 equal monthly settlements, as
measured against Benchmark Price. The actual consideration is variable
depending upon ImmuPharma's share price, which needs to be on average (over
the 24 months of the sharing agreement) at or above the Benchmark price for
the Company to receive at least, or more than, the gross subscription of £1
million.
For example, if on a monthly settlement date the calculated "Measured Price"
(average of twenty day ImmuPharma share VWAP) exceeds the Benchmark Price by
10 per cent, the settlement on that monthly settlement date will be 110 per
cent of the amount due from Lanstead on that date. If on the monthly
settlement date the calculated "Measured Price" is below the Benchmark Price
by 10 per cent, the settlement on the monthly settlement date will be 90 per
cent of the amount due on that date.
The Company also agreed to issue Lanstead 1,400,000 ordinary shares in
connection with entering into the Sharing Agreement ("Value Payment Shares").
Impact on L1/Lind arrangement
The 25,640,254 options in the Company, held equally by L1 and Lind, (issued in
June 2020) exercisable at any time up to 10 June 2023, at 11p have been
amended, as a result of the August 2022 fundraising of issuing shares below
11p. The effect of the current fundraising is to amend the exercise price of
these options from 11p to 5p and to increase the number of options held by L1
and Lind from 25,640,254 to 56,408,558.
Warrants
In August 2022, Lanstead was issued 30,000,000 warrants (for 10 years term),
with an exercise price of 5.5p per share in return for foregoing the
entitlement to increase the benchmark price by 50% (from 14.6667p to 22p) in
relation to the 2021 sharing agreement (due to the amendment made to L1 and
Lind option arrangements).
In August 2022, Stanford Capital Partners "SCP"- the Company's broker was
issued 2,000,000 warrants with an exercise price of 5p per share for the
period of 10 years, in lieu of fees.
In August 2022, SCP and SI Capital were issued 500,000 warrants each, for the
period of 10 years, in lieu of fees, as part of the "Broker Option".
Exercise of options
On 24 August 2022, L1 has exercised options over 1,000,000 new ordinary shares
of 1p each at an exercise price of 5p per share, for a consideration of
£50,000.
On 30 August 2022, L1 has exercised options over 2,000,000 new ordinary shares
of 1p each at an exercise price of 5p per share, for a consideration of
£100,000.
On 7 September 2022, L1 has exercised options over 3,000,000 new ordinary
shares of 1p each at an exercise price of 5p per share, for a consideration of
£150,000.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END IR UKAWRUBUKUARRecent news on ImmuPharma
See all newsREG - Immupharma PLC Incanthera PLC - Extension of Warrants in Incanthera to 30 Sep 2025
AnnouncementREG - Incanthera PLC Immupharma PLC - Warrant Extension, Debt Conversion & Equity Issue
AnnouncementRCS - Immupharma PLC - IMM attending Bio-Europe Spring 17-19 March,Milan
AnnouncementREG - Immupharma PLC - ImmuPharma proves unique Mechanism of Action-P140
AnnouncementREG - Immupharma PLC - Holding(s) in Company
Announcement